地塞米松-话题@MedSci

#地塞米松#

17篇内容 | 4858人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2213418, encodeId=f6762213418e4, content=<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a> <a href='/topic/show?id=0360144540e' target=_blank style='color:#2F92EE;'>#POEMS综合征#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=【BJH】伊沙佐米、环磷酰胺、地塞米松治疗新诊断POEMS综合征的疗效和安全性, objectType=article, longId=833004, objectId=fe75833004d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720150785862_5579292.jpg, objectUrl=/article/show_article.do?id=fe75833004d3, replyNumber=0, likeNumber=109, createdTime=2024-07-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fe75833004d3, moduleTitle=【BJH】伊沙佐米、环磷酰胺、地塞米松治疗新诊断POEMS综合征的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe75833004d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212995, encodeId=33d422129950c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a>, objectTitle=【AJH】伊沙佐米、达雷妥尤单抗、地塞米松治疗RRMM的2期研究结果, objectType=article, longId=832650, objectId=56c18326500f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1719977403583_5579292.png, objectUrl=/article/show_article.do?id=56c18326500f, replyNumber=0, likeNumber=170, createdTime=2024-07-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=56c18326500f, moduleTitle=【AJH】伊沙佐米、达雷妥尤单抗、地塞米松治疗RRMM的2期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56c18326500f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209282, encodeId=08472209282e1, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=901a1153803e' target=_blank style='color:#2F92EE;'>#Dara-KRd#</a>, objectTitle=【BCJ】24周期Dara-KRd不伴移植治疗新诊断多发性骨髓瘤的II期研究结果, objectType=article, longId=829410, objectId=ee6282941093, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240610/1718033892155_5579292.png, objectUrl=/article/show_article.do?id=ee6282941093, replyNumber=0, likeNumber=148, createdTime=2024-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ee6282941093, moduleTitle=【BCJ】24周期Dara-KRd不伴移植治疗新诊断多发性骨髓瘤的II期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee6282941093)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207616, encodeId=af07220e6163b, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3146892e7c7' target=_blank style='color:#2F92EE;'>#血液恶性肿瘤#</a> <a href='/topic/show?id=f52851329b' target=_blank style='color:#2F92EE;'>#Covid-19#</a>, objectTitle=Haematologica：地塞米松治疗COVID-19增加血液恶性肿瘤患者死亡率, objectType=article, longId=828174, objectId=6f7a8281e4c0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240530/1717040917076_5579292.jpg, objectUrl=/article/show_article.do?id=6f7a8281e4c0, replyNumber=0, likeNumber=247, createdTime=2024-05-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6f7a8281e4c0, moduleTitle=Haematologica：地塞米松治疗COVID-19增加血液恶性肿瘤患者死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f7a8281e4c0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203437, encodeId=46f6220343e1f, content=<a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>, objectTitle=Leukemia：硼替佐米+ R-HAD治疗R/R MCL的3期研究结果, objectType=article, longId=824888, objectId=c5f8824888c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=c5f8824888c2, replyNumber=0, likeNumber=172, createdTime=2024-05-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c5f8824888c2, moduleTitle=Leukemia：硼替佐米+ R-HAD治疗R/R MCL的3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5f8824888c2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195820, encodeId=646d219582061, content=<a href='/topic/show?id=0b8611283e05' target=_blank style='color:#2F92EE;'>#激素退烧#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3b746980125' target=_blank style='color:#2F92EE;'>#甲强龙#</a>, objectTitle=激素退烧到底是用「地塞米松」还是「甲强龙」？, objectType=article, longId=818152, objectId=c6e881815285, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016434455_4754896.png, objectUrl=/article/show_article.do?id=c6e881815285, replyNumber=0, likeNumber=132, createdTime=2024-03-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c6e881815285, moduleTitle=激素退烧到底是用「地塞米松」还是「甲强龙」？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6e881815285)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194028, encodeId=e45a21940280c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a> <a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>, objectTitle=Haematologica | 卡非佐米、沙利度胺和地塞米松用于多发性骨髓瘤复发或难治患者：ALLG MM018/AMN002 单臂多中心II期研究的最终报告, objectType=article, longId=817445, objectId=402581e445ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240318/1710773828708_6145188.png, objectUrl=/article/show_article.do?id=402581e445ba, replyNumber=0, likeNumber=138, createdTime=2024-03-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=402581e445ba, moduleTitle=Haematologica | 卡非佐米、沙利度胺和地塞米松用于多发性骨髓瘤复发或难治患者：ALLG MM018/AMN002 单臂多中心II期研究的最终报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=402581e445ba)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192245, encodeId=b9722192245de, content=<a href='/topic/show?id=8e0d10065ff' target=_blank style='color:#2F92EE;'>#isatuximab#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=79f9112091aa' target=_blank style='color:#2F92EE;'>#难治性多发性骨髓瘤#</a>, objectTitle=【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果, objectType=article, longId=816538, objectId=d333816538ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=d333816538ff, replyNumber=0, likeNumber=121, createdTime=2024-03-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d333816538ff, moduleTitle=【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d333816538ff)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191184, encodeId=c5ef21911846d, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=9eb09396903' target=_blank style='color:#2F92EE;'>#达雷木单抗#</a> <a href='/topic/show?id=b8dc111936b6' target=_blank style='color:#2F92EE;'>#塞利尼索(selinexor)#</a>, objectTitle=Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究, objectType=article, longId=816015, objectId=03c381601523, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/ksumc-evidencebased-clinical-practice-guidelines-program-overview-20132014-1-638.jpg, objectUrl=/article/show_article.do?id=03c381601523, replyNumber=0, likeNumber=160, createdTime=2024-03-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=03c381601523, moduleTitle=Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03c381601523)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190377, encodeId=68f521903e7ff, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=12ab111e84e7' target=_blank style='color:#2F92EE;'>#来那度胺暴露#</a>, objectTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, objectType=article, longId=815280, objectId=9d6981528062, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-hospital-corridor-with-medical-staff-and-PHNLKBC.jpg, objectUrl=/article/show_article.do?id=9d6981528062, replyNumber=0, likeNumber=116, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9d6981528062, moduleTitle=【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6981528062)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188739, encodeId=fb612188e39c8, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=a4671201218' target=_blank style='color:#2F92EE;'>#MM#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=1bf011141e3e' target=_blank style='color:#2F92EE;'>#塞利尼索#</a>, objectTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, objectType=article, longId=814080, objectId=882f81408000, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=882f81408000, replyNumber=0, likeNumber=124, createdTime=2024-02-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=882f81408000, moduleTitle=【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=882f81408000)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184584, encodeId=b16f218458489, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>, objectTitle=『地塞米松』用于哪几种退热合理？这11种情况一定斟酌再使用！, objectType=article, longId=811019, objectId=2e5a811019d6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221115/1668552845473_4754896.jpeg, objectUrl=/article/show_article.do?id=2e5a811019d6, replyNumber=0, likeNumber=98, createdTime=2024-01-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2e5a811019d6, moduleTitle=『地塞米松』用于哪几种退热合理？这11种情况一定斟酌再使用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e5a811019d6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183312, encodeId=04e12183312b2, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a>, objectTitle=【Haematologica】KTd方案治疗RRMM的II期研究显示安全有效, objectType=article, longId=810478, objectId=f1e48104e8b5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing.jpg, objectUrl=/article/show_article.do?id=f1e48104e8b5, replyNumber=0, likeNumber=114, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=f1e48104e8b5, moduleTitle=【Haematologica】KTd方案治疗RRMM的II期研究显示安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1e48104e8b5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181553, encodeId=643a2181553d2, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=391935910a2' target=_blank style='color:#2F92EE;'>#华氏巨球蛋白血症#</a> <a href='/topic/show?id=27951100e629' target=_blank style='color:#2F92EE;'>#RCD#</a> <a href='/topic/show?id=b0f01100e7cb' target=_blank style='color:#2F92EE;'>#BCD#</a>, objectTitle=【Haematologica】易树华/邱录贵团队对比RCD和BCD治疗症状性WM的随机对照研究, objectType=article, longId=809206, objectId=8c138092068b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/nurse-writing-on-a-clipboard-in-the-hospital-PZ3P5XL.jpg, objectUrl=/article/show_article.do?id=8c138092068b, replyNumber=0, likeNumber=115, createdTime=2024-01-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=8c138092068b, moduleTitle=【Haematologica】易树华/邱录贵团队对比RCD和BCD治疗症状性WM的随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c138092068b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177467, encodeId=b3f921e7467fc, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, objectType=article, longId=806561, objectId=31fe806561d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=31fe806561d8, replyNumber=0, likeNumber=108, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31fe806561d8, moduleTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31fe806561d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2167540, encodeId=9df7216e540e0, content=<a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>、<a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a>和<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>治疗<a href='/topic/show?id=288810e4102f' target=_blank style='color:#2F92EE;'>#NDMM合并肾损伤#</a>的中国研究, objectTitle=【Blood Adv】泊马度胺、硼替佐米和地塞米松治疗NDMM合并肾损伤的中国研究, objectType=article, longId=799894, objectId=a6c6e9989458, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=a6c6e9989458, replyNumber=0, likeNumber=150, createdTime=2023-11-09, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a6c6e9989458, moduleTitle=【Blood Adv】泊马度胺、硼替佐米和地塞米松治疗NDMM合并肾损伤的中国研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6c6e9989458)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2161487, encodeId=019b216148e54, content=<a href='/topic/show?id=d9e910508044' target=_blank style='color:#2F92EE;'>#分子胶降解剂#</a><a href='/topic/show?id=54c81050814e' target=_blank style='color:#2F92EE;'>#Mezigdomide#</a>（<a href='/topic/show?id=4ca810682632' target=_blank style='color:#2F92EE;'>#美齐格米特#</a>）联合<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>治疗<a href='/topic/show?id=c717425931e' target=_blank style='color:#2F92EE;'>#复发难治性多发性骨髓瘤#</a>，这个研究也有望进入2023年度<a href='/topic/show?id=ae41356995a' target=_blank style='color:#2F92EE;'>#十大#</a>研究，毕竟这是新一代的药物, objectTitle=NEJM：分子胶降解剂Mezigdomide（美齐格米特）联合地塞米松治疗复发难治性多发性骨髓瘤, objectType=article, longId=789734, objectId=8174e897342c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230902/1693621861459_6145188.jpg, objectUrl=/article/show_article.do?id=8174e897342c, replyNumber=0, likeNumber=115, createdTime=2023-10-08, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8174e897342c, moduleTitle=NEJM：分子胶降解剂Mezigdomide（美齐格米特）联合地塞米松治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8174e897342c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2117668, encodeId=cacb211e6689a, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>联合<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>和<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>治疗复发或难治性<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], objectType=guider, longId=22614, objectId=1d7071c00299e514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=1d7071c00299e514, replyNumber=2, likeNumber=147, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1d7071c00299e514, moduleTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=1d7071c00299e514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2121876, encodeId=fc6321218e6f5, content=在临床前骨髓瘤模型中，<a href='/topic/show?id=368d105e1469' target=_blank style='color:#2F92EE;'>#iberdomide#</a>已显示出与<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>、<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>和<a href='/topic/show?id=229b105e153a' target=_blank style='color:#2F92EE;'>#CD38单克隆抗体#</a>的协同作用，治疗<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>，同样也显示出对<a href='/topic/show?id=257ae692755' target=_blank style='color:#2F92EE;'>#系统性红斑狼疮#</a>的治疗活性, objectTitle=Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤, objectType=article, longId=741920, objectId=512be41920f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202201007/1665126448581_2110107.JPG, objectUrl=/article/show_article.do?id=512be41920f4, replyNumber=0, likeNumber=198, createdTime=2023-03-26, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=512be41920f4, moduleTitle=Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512be41920f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2111276, encodeId=699521112e6b9, content=<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a>感染诱导过度<a href='/topic/show?id=53c66e0011b' target=_blank style='color:#2F92EE;'>#炎症#</a>反应的潜在分子机制，ZBP1-<a href='/topic/show?id=c3bd1549545' target=_blank style='color:#2F92EE;'>#RIPK3#</a>轴在SARS-CoV-2诱导的炎症反应中起着关键作用，ZBP1-RIPK3通路可能是COVID-19抗炎治疗的新靶点。常规免疫抑制药物的进展，如<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>、氢化可的松、<a href='/topic/show?id=203ce2170be' target=_blank style='color:#2F92EE;'>#皮质类固醇#</a>，已报告没有或有限改善患者的结局。 , objectTitle=Cell Research：中国科学院彭珂等团队合作发现新冠病毒感染诱导过度炎症反应的潜在分子机制, objectType=article, longId=757068, objectId=6aa5e570687a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/confident-experienced-doctor-NJVKHS4.jpg, objectUrl=/article/show_article.do?id=6aa5e570687a, replyNumber=0, likeNumber=197, createdTime=2023-01-24, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6aa5e570687a, moduleTitle=Cell Research：中国科学院彭珂等团队合作发现新冠病毒感染诱导过度炎症反应的潜在分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa5e570687a)], followStatus=false, userIsMember=false, type=1, lengthMark=1)] 梅斯话题小助手

地塞米松

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#环磷酰胺# #POEMS综合征# #地塞米松# #伊沙佐米#

【BJH】伊沙佐米、环磷酰胺、地塞米松治疗新诊断POEMS综合征的疗效和安全性

2024-07-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #地塞米松# #伊沙佐米# #达雷妥尤单抗#

【AJH】伊沙佐米、达雷妥尤单抗、地塞米松治疗RRMM的2期研究结果

2024-07-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #来那度胺# #地塞米松# #Dara-KRd#

【BCJ】24周期Dara-KRd不伴移植治疗新诊断多发性骨髓瘤的II期研究结果

2024-06-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #血液恶性肿瘤# #Covid-19#

Haematologica：地塞米松治疗COVID-19增加血液恶性肿瘤患者死亡率

2024-05-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#硼替佐米# #套细胞淋巴瘤# #地塞米松#

Leukemia：硼替佐米+ R-HAD治疗R/R MCL的3期研究结果

2024-05-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#激素退烧# #地塞米松# #甲强龙#

激素退烧到底是用「地塞米松」还是「甲强龙」？

2024-03-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #卡非佐米# #沙利度胺# #地塞米松#

Haematologica | 卡非佐米、沙利度胺和地塞米松用于多发性骨髓瘤复发或难治患者：ALLG MM018/AMN002 单臂多中心II期研究的最终报告

2024-03-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#isatuximab# #泊马度胺# #地塞米松# #难治性多发性骨髓瘤#

【血液学】Isatuximab+泊马度胺+地塞米松治疗RRMM的3期研究最终OS结果

2024-03-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #硼替佐米# #地塞米松# #达雷木单抗# #塞利尼索(selinexor)#

Haematologica | 塞利尼索 + 达雷木单抗 + 硼替佐米 + 地塞米松四联疗法治疗复发难治性多发性骨髓瘤的II期临床研究

2024-03-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #地塞米松# #伊沙佐米# #达雷妥尤单抗# #来那度胺暴露#

【AJH】达雷妥尤单抗+伊沙佐米+地塞米松治疗来那度胺暴露二线RRMM的2期DARIA研究结果

2024-03-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #MM# #地塞米松# #达雷妥尤单抗# #塞利尼索#

【Haematologica】塞利尼索+达雷妥尤单抗+Vd治疗RRMM的II期研究

2024-02-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松#

『地塞米松』用于哪几种退热合理？这11种情况一定斟酌再使用！

2024-01-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #沙利度胺# #地塞米松# #卡非佐米#

【Haematologica】KTd方案治疗RRMM的II期研究显示安全有效

2024-01-22发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #华氏巨球蛋白血症# #RCD# #BCD#

【Haematologica】易树华/邱录贵团队对比RCD和BCD治疗症状性WM的随机对照研究

2024-01-14发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #泊马度胺# #达雷妥尤单抗# #RRMM#

2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS

2023-12-27发表于上海

(审核中...)

前往app查看评论内容

#泊马度胺#、#硼替佐米#和#地塞米松#治疗#NDMM合并肾损伤#的中国研究

【Blood Adv】泊马度胺、硼替佐米和地塞米松治疗NDMM合并肾损伤的中国研究

2023-11-09发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#分子胶降解剂##Mezigdomide#（#美齐格米特#）联合#地塞米松#治疗#复发难治性多发性骨髓瘤#，这个研究也有望进入2023年度#十大#研究，毕竟这是新一代的药物

NEJM：分子胶降解剂Mezigdomide（美齐格米特）联合地塞米松治疗复发难治性多发性骨髓瘤

2023-10-08发表于上海

lifestar (审核中...)

前往app查看评论内容

#伊沙佐米#联合#来那度胺#和#地塞米松#治疗复发或难治性#多发性骨髓瘤#

2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870]

2023-03-05发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

在临床前骨髓瘤模型中，#iberdomide#已显示出与#地塞米松#、#蛋白酶体抑制剂#和#CD38单克隆抗体#的协同作用，治疗#多发性骨髓瘤#，同样也显示出对#系统性红斑狼疮#的治疗活性

Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤

2023-03-26发表于上海

showtest (审核中...)

前往app查看评论内容

全文收起 #新冠病毒#感染诱导过度#炎症#反应的潜在分子机制，ZBP1-#RIPK3#轴在SARS-CoV-2诱导的炎症反应中起着关键作用，ZBP1-RIPK3通路可能是COVID-19抗炎治疗的新靶点。常规免疫抑制药物的进展，如#地塞米松#、氢化可的松、#皮质类固醇#，已报告没有或有限改善患者的结局。

Cell Research：中国科学院彭珂等团队合作发现新冠病毒感染诱导过度炎症反应的潜在分子机制

2023-01-24发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务